Difference between revisions of "Dosulepine-fluvoxamine"

From Psychiatrienet
Jump to: navigation, search
 
(3 intermediate revisions by 2 users not shown)
Line 3: Line 3:
 
| to = fluvoxamine
 
| to = fluvoxamine
 
| stop =  
 
| stop =  
* '''Before day 0:''' gradually reduce dosage of dosulepine to a maximum of 75 mg/day.
+
{{stopDosulepine}}
* '''Day 1:''' reduce dosage of dosulepine to 50 mg/day.
 
* '''Day 3:''' reduce dosage of dosulepine to 25 mg/day.
 
* '''Day 7:''' stop administration of dosulepine
 
 
| start =  
 
| start =  
* '''Day 8:''' start administration of fluvoxamine in a normal dosage of 50 mg/day.
+
* '''Day 9:''' start administration of fluvoxamine in a normal dosage of 50 mg/day.
 
| info =  
 
| info =  
* Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.}}
+
* {{theorSS}}
 +
* Fluvoxamine is an inhibitor of CYP1A2, CYP2C19 and CYP3A4 (moderate), which metabolize dosulepine.
 +
}}

Latest revision as of 13:10, 2 November 2015

dosulepin
Type antidepressant
Group TCA
links
ATC-code N06AA16
PubChem 13473
PubMed dosulepin
Kompas (Dutch) dosulepin
Wikipedia dosulepin
Fluvoxamine
Type Antidepressant
Group SSRI
links
Medscape Fluvoxamine
PubChem 5324346
PubMed Fluvoxamine
Kompas (Dutch) Fluvoxamine
Wikipedia Fluvoxamine

Switch medication from dosulepine to fluvoxamine.[1] [2]

Nietinrijdenbord.png Stop dosulepine
  • Before day 1: gradually reduce dosage of dosulepine to a maximum of 75 mg/ day, when this dosage is > 75 mg/day.
  • Day 1-3: reduce dosage of dosulepine to 50 mg/day.
  • Day 4-7: reduce dosage of dosulepine to 25 mg/day.
  • Day 8: stop administration of dosulepine.
Eenrichtingbord.png Start fluvoxamine
  • Day 9: start administration of fluvoxamine in a normal dosage of 50 mg/day.
Infobord.png More information
  • Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
  • Fluvoxamine is an inhibitor of CYP1A2, CYP2C19 and CYP3A4 (moderate), which metabolize dosulepine.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.